Nebulizer System Delivers Treatment Into COVID-19 Patient's Lungs

Galway Ireland based Aerogen announced an agreement with Synairgen plc, a Southampton, UK-based biotechnology company on October 22, 2020, to provide Aerogen Solo/Ultra nebulizer system for delivery of SNG001, an inhaled interferon beta that stimulates the innate immune system, directly into the lungs of COVID-19 patients.

Initial investigation of SNG001 as a potential COVID-19 treatment has been promising – hospitalized patients receiving SNG001 were at reduced risk of developing severe disease and more than twice as likely to recover to the ‘no limitation of activities’ level on the ordinal scale over the course of treatment, stated the company.

During July 2020, Richard Marsden, CEO of Synairgen, said: "We are all delighted with the trial results announced today, which showed that SNG001 greatly reduced the number of hospitalized COVID-19 patients who progressed from ‘requiring oxygen’ to ‘requiring ventilation’.